The positive results from the 12-month ARCH study support the hypothesis that a reduction in contraction-induced muscle damage in muscular dystrophies, associated with EDG-5506 administration, has the potential to preserve and improve muscle function while preventing disease progression in dystrophinopathies. Observations from ARCH identified key factors, including the optimal dosing strategy of EDG-5506, for the design of a potentially registrational trial. A pivotal cohort, GRAND CANYON, has been added to the CANYON study and is anticipated to begin enrollment in the third quarter of 2023.

SEE UPDATE FROM OCTOBER 30, 2023 HERE CLICK BELOW FOR A FEW WORDS FROM OUR TEAM AND SAREPTA: Sarepta Therapeutics’ gene therapy for Duchenne, SRP-9001, has been granted Accelerated Approval […]

PARAMUS, NJ: April 14, 2023,–NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA)has agreed to the planned Phase II study of NS-089/NCNP-02 for Duchenne muscular dystrophy. NS-089/NCNP-02 […]